Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Trial Profile

Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs JTX 4014 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Jounce Therapeutics
  • Most Recent Events

    • 28 Dec 2018 Status changed from planning to recruiting.
    • 28 Nov 2018 New trial record
    • 13 Nov 2018 According to a Jounce Therapeutics media release, the company filed an Investigational New Drug (IND) application for JTX-4014 in September 2018. The U.S. Food and Drug Administration (FDA) approved the IND in October 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top